X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bitolterol | Bitolterol mesylate is a beta-2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001. (Wikipedia) Pharmacology: Bitolterol, an adrenergic bronchodilator, is a prodrug that widens constricted airways in the lungs by relaxing the smooth muscles that surround the bronchial passages. Bitolterol probably does not affect the inflammation in the lung, such as in bronchitis. Bitolterol is unique in that it is a prodrug because it must first be metabolized by the body before it becomes active. Mechanism of action: Bitolterol is an adrenergic beta-2 agonist. Asthma is a breathing involving narrowing of the bronchial tubes. This narrowing is caused by muscle spasm and inflammation within the bronchial tubes. Bitolterol relaxes the smooth muscles surrounding these airway tubes, therefore, increases the diameter and ease of air flow through the tubes. Drug type: Small Molecule. Withdrawn. Drug category: Bronchodilator Agents. Selective beta-2-adrenoreceptor agonists | ILX:0101320 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bits Allocated | Number of bits allocated for each pixel sample. Each sample shall have the same number of bits allocated. | ILX:0101321 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Bits Stored | Number of bits stored for each pixel sample. Each sample shall have the same number of bits stored. See PS 3.5 for further explanation. | ILX:0101322 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bitter taste sensation | ILX:0101323 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bitufted | Two tufts in opposite directions | ILX:0101324 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bivalirudin | Synthetic 20 residue peptide (thrombin inhibitor) Pharmacology: Angiomax directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release Mechanism of action: Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Drug type: Approved. Biotech. Investigational. Drug category: Anticoagulants. Antithrombotic Agents | ILX:0101325 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Black | A color that lacks any hues as parts. | ILX:0101326 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula cat | An early stage of embryonic development where implantation in the wall of the uterus occurs, 30 to 40 hours. | ILX:0101327 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula dog | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 9 to 15. | ILX:0101328 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula ferret | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4.5 to 6. | ILX:0101329 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula human | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 6. | ILX:0101330 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula mouse | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 5. | ILX:0101331 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula rat | An early stage of embryonic development where implantation in the wall of the uterus occurs, days 4 to 5. | ILX:0101332 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blastula xenopus | An early stage of embryonic development where the blastomeres become arranged around the outside, with a central fluid filled cavity, the blastocoel (3 to 7 hours) OR the stages from 64-cell embryo to Nieuwkoop and Faber stage 9, during which the solid morula acquires an internal cavity. (Xenopus anatomy and development: http://purl.org/obo/owl/XAO#XAO_1000003) | ILX:0101333 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blattaria | ILX:0101334 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Blattidae | ILX:0101335 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Blattinae | ILX:0101336 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bleomycin | A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. (PubChem) Pharmacology: Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases). Mechanism of action: Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. Drug type: Approved. Small Molecule. Drug category: Antibiotics, Antineoplastic. Antimetabolites | ILX:0101337 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Blistered | ILX:0101338 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Block Data | A data stream of (x,y) pairs which comprise the block edge. The number of pairs shall be equal to Block Number of Points (300A,0104), and the vertices shall be interpreted as a closed polygon. | ILX:0101339 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X